A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.
Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses.



Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+B cells followed by positive selection of CD1c+PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals.



The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission.



This method was feasible and safe but was minimally immunogenic.
Ludwig Institute for Cancer Research, Victoria, Australia.|Austin Health, Department of Medical Oncology, Victoria, Australia.|Monash University Eastern Health Clinical School, Level 2, 5 Arnold St, Box Hill, Victoria 3128, Australia.|Eastern Health, Victoria, Australia.
Ian D
ID
Davis
Ludwig Institute for Cancer Research, Victoria, Australia.
Juliet
J
Quirk
Ludwig Institute for Cancer Research, Victoria, Australia.
Leone
L
Morris
Ludwig Institute for Cancer Research, Victoria, Australia.
Lauren
L
Seddon
Ludwig Institute for Cancer Research, Victoria, Australia.
Tsin Yee
TY
Tai
Ludwig Institute for Cancer Research, Victoria, Australia.
Genevieve
G
Whitty
Ludwig Institute for Cancer Research, Victoria, Australia.
Tina
T
Cavicchiolo
Ludwig Institute for Cancer Research, Victoria, Australia.
Lisa
L
Ebert
Ludwig Institute for Cancer Research, Victoria, Australia.
Heather
H
Jackson
Austin Health, Department of Anatomical Pathology, Victoria, Australia.
Judy
J
Browning
Austin Health, Department of Anatomical Pathology, Victoria, Australia.
Duncan
D
MacGregor
Miltenyi Biotec, Germany.
Frederick
F
Wittke
Miltenyi Biotec, Germany.
Gregor
G
Winkels
Miltenyi Biotec, Germany.
Regina
R
Alex
CSL Limited, Melbourne, Australia.
Lena
L
Miloradovic
Ludwig Institute for Cancer Research, Victoria, Australia.|CSL Limited, Melbourne, Australia.
Eugene
E
Maraskovsky
Ludwig Institute for Cancer Research, Victoria, Australia.|School of Cancer Medicine, La Trobe University, Australia.
Weisan
W
Chen
Ludwig Institute for Cancer Research, Victoria, Australia.|Austin Health, Department of Medical Oncology, Victoria, Australia.|School of Cancer Medicine, La Trobe University, Australia.|Olivia Newton-John Cancer Research Institute, Victoria, Australia.
Jonathan
J
Cebon
D000368:Aged; D017951:Antigen Presentation; D018949:Antigens, CD1 / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000378:metabolism; D001773:Blood Cells / Q000502:physiology* / Q000637:transplantation; D019496:Cancer Vaccines / Q000276:immunology*; D002280:Basal Cell Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D003713:Dendritic Cells / Q000502:physiology* / Q000637:transplantation; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D056724:Immunity, Humoral; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010743:Phospholipids / Q000378:metabolism; D010865:Pilot Projects; D012503:Saponins / Q000378:metabolism; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
D018949:Antigens, CD1; D000951:Antigens, Neoplasm; C437944:CD1C protein, human; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D004338:Drug Combinations; D006023:Glycoproteins; C493786:ISCOMATRIX; D008565:Membrane Proteins; D010743:Phospholipids; D012503:Saponins; D002784:Cholesterol
ISCOMATRIX™ adjuvant; NY-ESO-1; antigens; clinical trial; dendritic cells